ClearBridge Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

ClearBridge Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-394	Closed	-$19K	–	782
2020 Q2	$19K	Hold	394	–	–	﹤0.01%	847
2020 Q1	$17K	Sell	394 -806	-67%	-$33.2K	﹤0.01%	897
2019 Q4	$49K	Buy	1,200 +200	+20%	+$8.7K	﹤0.01%	828
2019 Q3	$36K	Hold	1,000	–	–	﹤0.01%	862
2019 Q2	$27K	Hold	1,000	–	–	﹤0.01%	910
2019 Q1	$27K	Buy	+1,000	New	+$23.4K	﹤0.01%	915
2018 Q2	–	Sell	-1,250	Closed	-$28K	–	1153
2018 Q1	$28K	Hold	1,250	–	–	﹤0.01%	936
2017 Q4	$38K	Buy	1,250 +500	+67%	+$16K	﹤0.01%	892
2017 Q3	$28K	Hold	750	–	–	﹤0.01%	992
2017 Q2	$21K	Sell	750 -1,250	-63%	-$37.3K	﹤0.01%	1034
2017 Q1	$69K	Hold	2,000	–	–	﹤0.01%	841
2016 Q4	$58K	Buy	+2,000	New	+$52.9K	﹤0.01%	873
2016 Q3	–	Sell	-500	Closed	-$16K	–	1116
2016 Q2	$16K	Sell	500 -500	-50%	-$16.7K	﹤0.01%	952
2016 Q1	$28K	Buy	1,000 +400	+67%	+$8.72K	﹤0.01%	917
2015 Q4	$21K	Buy	600 +100	+20%	+$3.52K	﹤0.01%	974
2015 Q3	$17K	Buy	500 +200	+67%	+$8.32K	﹤0.01%	1034
2015 Q2	$13K	Buy	+300	New	+$11.6K	﹤0.01%	1056

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

ClearBridge Investments's ACAD Position: Q3 2020 in Review

ClearBridge Investments sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 394 shares — an estimated $19K sold.

ClearBridge Investments first reported a position in ACAD in Q2 2015 and held it in 17 quarters. The position peaked at $69K in Q1 2017. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

ClearBridge Investments reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
ClearBridge Investments sold 394 Acadia Pharmaceuticals shares in Q3 2020, an estimated $19K.
ClearBridge Investments first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 17 quarters.
ClearBridge Investments's Acadia Pharmaceuticals position peaked at $69K in Q1 2017.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on ClearBridge Investments's 13F filing for Q3 2020, filed 12 Nov 2020.